ELMIND CAPITAL LP
Q4 2025 Form 13-F

NEW YORK, DELAWARE
CIK 0002052213 · CRD 333910 · SEC-registered investment adviser
$338.9M Reported Value Total

ELMIND CAPITAL LP reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $613,614,919, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
1 fund · $613.6M gross asset value
Hedge Fund: $613.6M
Source: Form ADV filed 2026-09-03
Reported value
$338.9M
Quarter over quarter
0.0%
Holdings
34
Top-10 concentration
68.6%

Key People

Form ADV owners & control persons
Lihan Sun
CHIEF INVESTMENT OFFICER AND LIMITED PARTNER
Ernest Joseph Verrico
CHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2025 13F record

Q4 2025 13F filing summary

Q4 2025 Form 13F portfolio summary
Period of report December 31, 2025
Filed February 17, 2026
Form 13F-HR
Reported value $338.9M
Positions 34
Change in reported value First reported quarter
Top-10 concentration 68.6%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
30 $403.8M
Q2 2026 13F
Filed Aug 14, 2026
35 $398.0M
Q1 2026 13F
Filed May 15, 2026
34 $352.2M
Q4 2025 13F
Filed Feb 17, 2026
34 $338.9M

Top 20 holdings · Q4 2025

Largest Q4 2025 13F positions by reported value
# Holding Reported value % of portfolio
1 COGT COGENT BIOSCIENCES INC $41.6M 12.27%
2 SNDX SYNDAX PHARMACEUTICALS INC $39.0M 11.5%
3 VRDN VIRIDIAN THERAPEUTICS INC $26.7M 7.89%
4 VERA VERA THERAPEUTICS INC $24.4M 7.21%
5 CLDX CELLDEX THERAPEUTICS INC NEW $23.5M 6.93%
6 CGON CG ONCOLOGY INC $20.4M 6.03%
7 BCRX BIOCRYST PHARMACEUTICALS INC $16.8M 4.95%
8 PCVX VAXCYTE INC $13.4M 3.97%
9 BEAM BEAM THERAPEUTICS INC $13.2M 3.9%
10 PHVS PHARVARIS N V $13.2M 3.9%
11 KALV KALVISTA PHARMACEUTICALS INC $12.9M 3.82%
12 DVAX DYNAVAX TECHNOLOGIES CORP $10.5M 3.09%
13 TYRA TYRA BIOSCIENCES INC $9.2M 2.72%
14 NRIX NURIX THERAPEUTICS INC $8.7M 2.58%
15 WVE WAVE LIFE SCIENCES LTD $7.6M 2.25%
16 MBX MBX BIOSCIENCES INC $6.7M 1.96%
17 KRYS KRYSTAL BIOTECH INC $5.4M 1.6%
18 UTHR UNITED THERAPEUTICS CORP DEL $5.4M 1.58%
19 BMRN BIOMARIN PHARMACEUTICAL INC $4.9M 1.44%
20 RLAY RELAY THERAPEUTICS INC $4.5M 1.34%

Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings